CNNMoney.com
Companies Economy International Corrections Pre-market Trading After-hours Trading Winners/Losers/Actives Bonds Currencies Commodities World Markets Subscribe to Real Money Newsletter Subscribe to Money Magazine Money Magazine Real Estate Taxes Jobs Ask the Expert Money 101 Autos Mutual Funds The Help Desk Loan Center Best Places to Live Subscribe to Money Magazine Ask the Expert Ultimate Guide to Retirement Retirement Calculators Rules of Retirement Best Funds Best Places to Retire Fortune Brainstorm Tech Apple 2.0 Blog Big Tech Blog Sectors and Stocks Tech Talk Questions & Answers Innovation Nation Small Business Video 50 Best Places to Launch Resource Guide Next Little Thing Subscribe to Fortune Magazine Fortune 500 Brainstorm Tech Investing Management Executive Interviews Rankings Main Create Portfolio Edit Portfolio Create Alerts Edit Alerts
U.S. Customs relaxes enforcement on drugs from Canada
Big Pharma opposes decision to allow limited importation of drugs over United States-Canada border
By Aaron Smith, CNNMoney.com staff writer

NEW YORK (CNNMoney.com) -- The U.S. Customs department is relaxing its enforcement on the importation from Canada of pharmaceutical drugs for personal use, much to the ire of the industry's trade organization.

"It appears innocent enough, but it's the first step down a dark, dangerous road," said Ken Johnson, senior vice president for the Pharmaceutical Research and Manufacturers of America, which represents drug makers and biotechs.

drugs_pills_hand.03.jpg

Lynn Hollinger, spokeswoman for U.S. Customs and Border Protection, said the enforcement agency will no longer automatically detain pharmaceuticals being brought into this country from Canada by private citizens.

Individuals will not be barred from bringing a 90-day supply for themselves into the U.S., so long as it carried over the border on their person, said Hollinger.

But Johnson of PhRMA said there is no way the Food and Drug Administration can ensure the authenticity of drugs that are brought into the country by private citizens.

"People think if it's coming back from Canada it must be safe, because Canada is like the U.S., but a lot of the drugs are coming from Third World countries," said Johnson. "We know drugs are being brought into Canada from places like Pakistan, China and Thailand. We have evidence of fake drugs being cooked up in bathtubs in Belize."

Johnson reiterated that even though personal importation is now tolerated, it remains illegal.

"If you buy drugs over the Internet or from Canada, and it makes you sick and kills you, who do you sue?" said Johnson. "Who is held liable?"

Last year, the FDA examined 4,000 parcels containing pharmaceuticals and passing through major U.S. airports, and 1,700 of them claimed that their drugs were made in Canada, said Hollinger. But of those 1,700 shipments, only 15 percent of them were actually made in Canada, while the rest were made in 27 different countries, and 10 percent of them were counterfeit.

The multi-billion dollar worldwide counterfeit drug industry is considered a threat to public health, because some of the drugs contain different active ingredients than what they claim, or no active ingredients at all.

Pfizer's Viagra, a treatment for sexual dysfunction in men, is a popular target for counterfeit, and OxyContin, a painkiller from Purdue Pharma, is a popular target for theft and abuse. Both of these companies have installed Radio Frequency Identification (RFID) chips in pallets containing drugs to track shipments and try to prevent theft.

Johnson of PhRMA said the counterfeiting of name-brand drugs is a "black eye" to the legitimate manufacturers.

"It not as much about sales, as it is the reputation of the company and the reputation to the drugs," said Johnson.

The legitimate drug industry includes Big Pharma giants like Pfizer (down $0.34 to $27.99, Charts), Merck (down $0.52 to $41.42, Charts), Bristol-Myers Squibb (down $0.10 to $24.52, Charts), Schering-Plough (up $0.17 to $22.10, Charts), Eli Lilly & Co (up $0.16 to $57.76, Charts)., Johnson & Johnson (down $0.72 to $65.11, Charts) and Abbott Laboratories (down $0.79 to $46.35, Charts), and biotechs like Amgen (up $1.76 to $74.73, Charts) and Genentech (up $1.30 to $83.70, Charts). Top of page

YOUR E-MAIL ALERTS
Follow the news that matters to you. Create your own alert to be notified on topics you're interested in.

Or, visit Popular Alerts for suggestions.
Manage alerts | What is this?
© 2010 Cable News Network. A Time Warner Company. All Rights Reserved. Terms under which this service is provided to you. Privacy Policy. Advertising Practices.
Copyright © 2010 BigCharts.com Inc. All rights reserved. Please see our Terms of Use.
MarketWatch, the MarketWatch logo, and BigCharts are registered trademarks of MarketWatch, Inc.
Intraday data provided by Interactive Data Real-Time Services and subject to the Terms of Use.
Intraday data is at least 20-minutes delayed. All times are ET.
Historical, current end-of-day data, and splits data provided by Interactive Data Pricing and Reference Data.
Fundamental data provided by Morningstar, Inc..
SEC Filings data provided by Edgar Online Inc..
Earnings data provided by FactSet CallStreet, LLC.